- Home
- Dabigatran and the Role of Reversal Agent
During urgent interventions, normalizing coagulation values is a crucial step. Professor Dr. Martin Grond emphasizes the administration of idarucizumab in patients undergoing emergency surgeries, as he shares his experience with the drug.
The availability of specific reversal agent can change lives of people on anticoagulation therapy. Idarucizumab is the specific reversal agent for dabigatran that can be utilized as a rescue strategy in clinical scenarios of life-threatening bleeding and urgent surgical or medical intervention. Given his in-clinic experiences, Professor Dr. Martin Grond couldn’t agree more.
A stroke can create long-term challenges for patients and caregivers. Novel oral anticoagulants help in the prevention of stroke in patients with atrial fibrillation. In cases when patients are for emergency procedure like IV thrombolysis for ischemic stroke and are on dabigatran, it is always reassuring to know that reversibility of NOAC effect is possible to proceed with contemplated procedure. Professor Dr. Martin Grond opines on managing such critical situations with a specific reversal agent like idarucizumab.
Professor Dr. Martin Grond shares his clinical experience about a patient with TIA and brain hemorrhage. He shares his practice experience on the possibility of controlling hematoma growth in patients taking anticoagulants with a specific antidote.
Professor Dr. Martin Grond describes idarucizumab, its mode of action and method of administration and elaborates how this reversal agent can provide value to dabigatran treated patients undergoing emergency surgery or with life-threatening bleeding.
In patient on effective anticoagulation therapy, suffering from an ischemic stroke, is thrombolysis possible? Know it better from Professor Dr. Martin Grond.
Use of direct oral anticoagulants has bridged the need for effective anticoagulation in patients with atrial fibrillation. Professor Anna Tomaszuk-Kazberuk throws light on the efficacy and safety of direct oral anticoagulants and use of idarucizumab to reverse their anticoagulant effect, when needed.
Professor Anna Tomaszuk-Kazberuk discusses a case where cardiac surgeons initially refused to operate a patient on anticoagulant treatment and how idarucizumab has paved the way for proceeding with the contemplated procedure.
Professor Anna Tomaszuk-Kazberuk elaborates on how the use of idarucizumab changed the opinion of cardiac surgeons from withholding an emergency procedure for an imminent life-threatening condition to performing the same, while the patient was on dabigatran.
An elderly lady who had previous stroke and maintained on dabigatran had massive bleeding from her genital tract, as seen by her gynecologist. Professor Anna Tomaszuk-Kazberuk tells us how idarucizumab served as her rescue drug.
There are circumstances that may need for emergency reversal of anticoagulation in order to save lives of patients. Professor Anna Tomaszuk-Kazberuk deliberates on the use of idarucizumab by citing different clinical scenarios which were successfully managed with administration of idarucizumab based on her clinical experience.
Prof. Dr. med. Martin Grond provides a neurologist’s perspective on the reversibility of NOAC therapies and in specific about reversing dabigatran anticoagulant effects using idarucizumab in life threatening emergency situations like ischemic stroke and ICH, based on a retrospective study and real-world experience.
DOACs carry a risk of bleeding as with all antithrombotic therapies. A humanized monoclonal antibody was developed to reverse dabigatran anticoagulant effects in rare emergency situations. Let us see the mechanism of action of this antidote, idarucizumab.
